$ADPT (Adeptus Health Inc.)

$ADPT {{ '2016-06-03T13:09:06+0000' | timeago}} • Announcement

$ADPT said it plans to use all of the net proceeds from the offering received by it to purchase, for cash, 1.54MM limited liability company units of Adeptus Health from certain of the unit holders of Adeptus Health, including certain of the company's directors and executive officers.

$AMGN {{ '2018-01-19T13:28:13+0000' | timeago}} • Announcement

The European Commission (EC) has granted marketing authorization for MVASI from $AMGN and $AGN. MVASI is the first biosimilar bevacizumab approved by the EC and is approved for the treatment of certain types of cancers.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$MD {{ '2018-01-10T15:20:12+0000' | timeago}} • Announcement

$MD announced the acquisition of Tri-Valley Neonatal Medical Group, Inc., a private neonatology physician practice based in California. This was a cash transaction and it is expected to be immediately accretive to earnings. No additional terms of the transaction were disclosed.

$SEM {{ '2018-01-09T18:17:01+0000' | timeago}} • Announcement

$SEM announced a JV agreement with Banner Health to combine operations of more than 38 physical therapy centers in Arizona and four acute inpatient rehabilitation hospitals in Phoenix. Banner Health will be the majority owner and $SEM will serve as managing partner.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$SEM {{ '2018-01-08T18:16:59+0000' | timeago}} • Announcement

$SEM expects consolidated net operating revenues for full year 2018 to be $5-5.2Bil. Adjusted EBITDA is expected to be $630-660MM. $SEM expects fully diluted income per common share for full year 2018 to be $0.97-1.12.

$THC {{ '2018-01-05T17:28:17+0000' | timeago}} • Announcement

$THC and St. Luke’s Hospital, an independent, non-profit healthcare provider, have entered into a definitive agreement for St. Luke’s to purchase Des Peres Hospital as well as Tenet-owned physician practices and other hospital-affiliated operations in St. Louis. The transaction is expected to be completed early in 2018.

$THC {{ '2018-01-04T22:16:28+0000' | timeago}} • Announcement

$THC and Baylor Scott & White Health plan to restructure their JV arrangements for three North Texas hospitals by spring of 2018. Baylor Scott & White will acquire $THC’s minority interest in Baylor Scott & White - Centennial and Baylor Scott & White - Lake Pointe. Baylor Scott & White - Sunnyvale will become part of Texas Health Ventures Group.

$THC {{ '2017-12-26T17:43:20+0000' | timeago}} • Announcement

$THC and Baylor Scott & White Health have agreed to sell Baylor Scott & White Medical Center - White Rock, a 218-bed hospital located in Dallas, Texas, to Pipeline Health, LLC. The hospital is part of a JV partnership with Baylor Scott & White Health, in which $THC is the minority owner. The transaction is expected to be completed in 1Q18.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$AGN {{ '2017-12-21T14:38:43+0000' | timeago}} • Announcement

$AGN and its partner $PRTK announced that FDA accepted to review Seysara, an investigational drug for treating acne. Allergan, which has the U.S. rights of developing and marketing Seysara, expects FDA to take action on this in 2H18. Paratek retains the non-U.S. rights. In March 2017, Allergan announced positive results from Seysara Phase 3 trials.

$HUM {{ '2017-12-19T15:27:46+0000' | timeago}} • Announcement

$HUM signed a definitive agreement to acquire a 40% minority interest in the Kindred at Home Division of $KND for an estimated cash consideration of approximately $800MM. Humana does not anticipate a material impact to earnings in 2017 from this pending transaction.

$KND {{ '2017-12-19T13:44:51+0000' | timeago}} • Announcement

$KND's BoD approved a definitive agreement whereby it will be acquired by a consortium of three companies: TPG Capital, Welsh, Carson, Anderson & Stowe and $HUM for about $4.1Bil in cash including the assumption or repayment of net debt. The transaction is expected to close during the summer of 2018.

$THC {{ '2017-12-19T13:06:16+0000' | timeago}} • Announcement

For FY18, $THC expects its net income to be in the range of $65-70MM with EPS of about $0.63-0.68. Adj. EPS is expected to be about $1.07-1.36. Net operating revenue is expected to be about $17.8-18.2Bil.

$THC {{ '2017-12-19T13:04:06+0000' | timeago}} • Announcement

$THC said it would explore a sale of its subsidiary Conifer. The company expects to make a decision regarding the sale during the first half of 2018. Goldman, Sachs & Co. LLC as its financial advisor and Kirkland & Ellis LLP are the legal advisor.

$THC {{ '2017-12-19T13:00:29+0000' | timeago}} • Announcement

$THC has increased the size of its previously announced cost reduction initiative by  $100MM. The company now expects to achieve $200MM of annualized savings by the end of 2018. $THC has also started a process to refresh the composition of its BoD. The board currently consists of 12 directors.

$AGN {{ '2017-12-18T22:26:29+0000' | timeago}} • Announcement

Robert Stewart, COO of $AGN will resign from his role. He has been named as the CEO of the newly formed Amneal Pharmaceuticals, effective Jan. 25, 2018. Following Rob's departure, Wayne Swanton, SVP, Global Operations has been promoted as EVP, Global Operations of Allergan.

$AGN {{ '2017-12-18T22:14:14+0000' | timeago}} • Announcement

$AGN and its development partner Gedeon Richter Plc reported positive results from phase 3 study of cariprazine, which is used to treat the bipolar depression. Allergan plans to file the New Drug Application to the FDA in 2H18.

$IPXL {{ '2017-12-18T13:05:53+0000' | timeago}} • Announcement

Amneal Pharmaceuticals LLC and $IPXL said Robert Stewart will join Amneal as President, effective Jan. 25, 2018. Stewart most recently served as COO of $AGN. After completion of combination of Amneal and $IPXL, Stewart will become President and CEO of the combined company, to be named Amneal Pharmaceuticals Inc., and will become a BoD member.

$AGN {{ '2017-12-12T19:58:45+0000' | timeago}} • Announcement

$AGN gets FDA clearance for the CoolSculpting, a treatment to improve the appearance of lax tissue in double chin. Allergan got this CoolSculpting technology by acquiring Zeltiq Aesthetics in Feb. 2017 for $2.4Bil. Allergan added that in an 18-week study, 77% of patients showed improved appearance in their lax tissue.

Recent Transcripts

RAD (Rite Aid Corporation)
Wednesday, January 3 2018 - 10:00pm
ONVO (Organovo Holdings, Inc.)
Thursday, November 9 2017 - 10:00pm
TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
FVE (Five Star Quality Care Inc.)
Thursday, November 9 2017 - 3:00pm
DVA (DaVita HealthCare Partners Inc.)
Tuesday, November 7 2017 - 10:00pm
THC (Tenet Healthcare Corp.)
Tuesday, November 7 2017 - 3:00pm
KND (Kindred Healthcare Inc.)
Tuesday, November 7 2017 - 2:00pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
SEM (Select Medical Holdings Corporation)
Friday, November 3 2017 - 1:00pm
FMS (Fresenius Medical Care AG & Co. KGAA)
Thursday, November 2 2017 - 8:30pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
MD (MEDNAX, Inc.)
Wednesday, November 1 2017 - 2:00pm
EVHC (Envision Healthcare Holdings, Inc.)
Wednesday, November 1 2017 - 12:30pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
HCA (HCA Holdings, Inc.)
Tuesday, October 31 2017 - 2:00pm
UHS (Universal Health Services Inc.)
Thursday, October 26 2017 - 1:00pm
RAD (Rite Aid Corporation)
Thursday, September 28 2017 - 12:30pm
PTN (Palatin Technologies Inc.)
Monday, September 25 2017 - 3:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, August 9 2017 - 9:00pm
THC (Tenet Healthcare Corp.)
Tuesday, August 8 2017 - 2:00pm

AlphaGraphics you may like